Evidence map›Paper›PMID 31558766›Full record

Trial reportLeukemia2019

Durable response with single-agent acalabrutinib in patients with relapsed or refractory mantle cell lymphoma.

Michael Wang, Simon Rule, Pier Luigi Zinzani, Andre Goy, Olivier Casasnovas, Stephen D Smith, Gandhi Damaj, Jeanette K Doorduijn, Thierry Lamy, Franck Morschhauser and 17 more

Abstract readClinical Trial, Phase IILetterMulticenter Study
PubMed Publisher
In one paragraph

Trial report in Leukemia, 2019. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 57 papers.

0numbers the graph read from it
0cells of the map it votes in
57citing papers in PubMed
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

57 citing papers in PubMed.

  1. Trial
  2. Trial
  3. Trial
  4. Trial
  5. Trial
  6. Trial
  7. Trial
  8. Review
  9. Article
  10. Review
  11. Article
  12. Article
  13. Article
  14. Article
  15. Review
  16. Review
  17. Review
  18. Review
  19. Review
  20. Review
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

27 authors.

Michael WangMD Anderson Cancer Center, University of Texas, Houston, TX, USA. miwang@mdanderson.org.ORCID http://orcid.org/0000-0001-9748-5486
Simon RulePlymouth University Medical School, Plymouth, UK.ORCID http://orcid.org/0000-0001-8937-6351
Pier Luigi ZinzaniInstitute of Hematology "Seràgnoli", University of Bologna, Bologna, Italy.
Andre GoyJohn Theurer Cancer Center, Hackensack University Medical Center, Hackensack, NJ, USA.
Olivier CasasnovasCHU Dijon - Hôpital d'Enfants, Dijon, France.
Stephen D SmithFred Hutchinson Cancer Research Center, University of Washington, Seattle, WA, USA.
Gandhi DamajInstitut d'Hématologie de Basse-Normandie, Caen, France.
Jeanette K DoorduijnErasmus MC, HOVON Lunenburg Lymphoma Phase I/II Consortium, Rotterdam, Netherlands.
Thierry LamyCHU de Rennes, Rennes, France.
Franck MorschhauserUniv. Lille, CHU Lille, EA 7365-GRITA-Groupe de Recherche sur les Formes Injectables et les Technologies Associées, F-59000, Lille, France.
Carlos PanizoClínica Universidad de Navarra, Pamplona, Spain.
Bijal ShahMoffitt Cancer Center, Tampa, FL, USA.
Andrew DaviesCancer Research UK Centre, University of Southampton Faculty of Medicine, Southampton, UK.
Richard EekBorder Medical Oncology, Albury, Victoria, Australia.
Jehan DupuisUnité Hémopathies Lymphoïdes, AP-HP Hôpital Henri Mondor, Créteil, France.
Eric JacobsenDana Farber Cancer Institute, Harvard Medical School, Boston, MA, USA.
Arnon P KaterCancer Center Amsterdam, Amsterdam University Medical Centers, University of Amsterdam, HOVON Lunenburg Lymphoma Phase I/II Consortium, Amsterdam, Netherlands.
Steven Le GouillCHU de Nantes-Hotel Dieu, Nantes, France.
Lucie ObericInstitut Universitaire du Cancer-Oncopole Toulouse (IUCT-O), Toulouse, France.
Tadeusz RobakCopernicus Memorial Hospital, Medical University of Lodz, Lodz, Poland.
Preetesh JainMD Anderson Cancer Center, University of Texas, Houston, TX, USA.
Melanie M FrigaultAcerta Pharma, South San Francisco, CA, USA.
Raquel IzumiAcerta Pharma, South San Francisco, CA, USA.
Dorothy NguyenAcerta Pharma, South San Francisco, CA, USA.
Priti PatelAcerta Pharma, South San Francisco, CA, USA.
Ming YinAcerta Pharma, South San Francisco, CA, USA.
Monika Długosz-DaneckaDepartment of Haematology, Jagiellonian University, Krakow, Poland.

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

PubMed holds no abstract for this paper.

Indexed as

Drug Resistance, NeoplasmAdultAgammaglobulinaemia Tyrosine KinaseAgedAged, 80 and overAntineoplastic AgentsBenzamidesCell ProliferationDisease ProgressionFemaleFollow-Up StudiesHumansKi-67 AntigenLymphoma, Mantle-CellMaleMiddle AgedacalabrutinibAgammaglobulinaemia Tyrosine KinaseAntineoplastic AgentsBenzamidesBTK protein, humanKi-67 AntigenPyrazines

Identifiers

PMID31558766

What OpenQuestion holds

Textmetadata
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.